Merck

Variational AI employs cutting-edge machine learning techniques to swiftly generate novel compounds optimized for multiple properties. This approach aims to mitigate common causes of drug failure and enhance clinical success. The company collaborates with leading biopharmaceutical partners and maintains its own pipeline.

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Personalis, Inc. is a cancer genomics company based in Menlo Park, California, that specializes in genomic sequencing and data analysis services aimed at advancing personalized cancer therapies. Established in 2011, the company offers a range of products, including the NeXT Platform, which provides critical data for the development of personalized therapies, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that examines various human genes to enhance cancer treatment strategies. The company's services support biopharmaceutical clients, universities, non-profit organizations, diagnostics companies, and government agencies, facilitating the creation of safer and more effective precision cancer therapies and immunotherapies. Personalis is recognized for its integration of sequencing technology and data interpretation, contributing to a comprehensive understanding of tumor biology and its interaction with the immune system.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Abceutics, headquartered in Buffalo, New York, is a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs.

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

AeroSafe Global is a U.S.-based company that develops and manufactures aerogels for thermal insulation, primarily serving the biopharmaceutical industry. Its products ensure reliable, sustainable, and simple temperature-sensitive supply chain solutions. AeroSafe Global specializes in cold-chain services, providing customized packaging, logistics, and operational services to prevent any temperature excursions during transportation of biomedical and pharmaceutical products.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.

Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

M2Gen, Corp. is a health informatics solutions company headquartered in Tampa, Florida, established in 2006 at the Moffitt Cancer Center. It specializes in advancing precision medicine through its integrated clinical and molecular data platform, which analyzes data to enhance patient care. M2Gen provides evidence-based solutions that help identify disease susceptibility, predict drug responses, and match patients with optimal therapies. The company operates the Total Cancer Care Protocol, a comprehensive approach that studies patients throughout their lifetime, and collaborates with leading cancer centers through the Oncology Research Information Exchange Network (ORIEN). Additionally, M2Gen offers the M2Gen Portfolio, which supports biopharmaceutical companies in discovering new targets and biomarkers, improving clinical trial design and enrollment, and facilitating long-term post-market analysis. M2Gen was formerly known as Moffitt Genetics Corporation, Inc. and rebranded in August 2017. It operates as a subsidiary of the H. Lee Moffitt Cancer Center & Research Institute.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

OncoImmune is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for cancer and autoimmune diseases. Its pipeline includes CD24Fc, a fusion protein for preventing acute graft-versus-host disease, and ONC-392, a monoclonal antibody designed to reduce immune-related toxicities.

Zapata Computing, Inc. is a quantum software company that specializes in developing innovative computing solutions tailored for industrial and commercial applications. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company emerged from Harvard University and is driven by a team of scientists, including Alán Aspuru-Guzik. Zapata offers Orquestra, a software platform that enables the composition of quantum workflows using a YAML-compatible language, facilitating tasks across both quantum and classical hardware. Its solutions are hardware-agnostic and cater to various sectors, including finance, healthcare, pharmaceuticals, transportation, logistics, energy, and more. Equipped to address complex challenges, Zapata Computing focuses on simulation, optimization, and machine learning, helping enterprise organizations harness the power of quantum technology to enhance their operations.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

AeroSafe Global is a U.S.-based company that develops and manufactures aerogels for thermal insulation, primarily serving the biopharmaceutical industry. Its products ensure reliable, sustainable, and simple temperature-sensitive supply chain solutions. AeroSafe Global specializes in cold-chain services, providing customized packaging, logistics, and operational services to prevent any temperature excursions during transportation of biomedical and pharmaceutical products.

Zapata Computing, Inc. is a quantum software company that specializes in developing innovative computing solutions tailored for industrial and commercial applications. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company emerged from Harvard University and is driven by a team of scientists, including Alán Aspuru-Guzik. Zapata offers Orquestra, a software platform that enables the composition of quantum workflows using a YAML-compatible language, facilitating tasks across both quantum and classical hardware. Its solutions are hardware-agnostic and cater to various sectors, including finance, healthcare, pharmaceuticals, transportation, logistics, energy, and more. Equipped to address complex challenges, Zapata Computing focuses on simulation, optimization, and machine learning, helping enterprise organizations harness the power of quantum technology to enhance their operations.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of targeted therapeutics for cancer and rare diseases. Founded in 1993 and headquartered in Burlington, Massachusetts, the company employs its ArQule Kinase Inhibitor Platform to design and develop novel small molecule drugs. ArQule's pipeline includes several investigational therapies, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase for B-cell malignancies; miransertib, an AKT inhibitor for advanced endometrial cancer; and ARQ 75, also targeting AKT in solid tumors. Additionally, Derazantinib is a multi-kinase inhibitor in clinical trials for intrahepatic cholangiocarcinoma. The company has established license agreements with Basilea Pharmaceutica and Roivant Sciences for its therapeutic candidates. As of January 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Tilos Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in antibodies that target the Latency Associated Peptide of TGF beta, which plays a crucial role in regulating immune responses. Tilos Therapeutics is particularly focused on the modulation of regulatory T cells and effector cell regulation, leveraging the immune system to create effective therapies. By enhancing treatment options, Tilos aims to enable patients to begin their therapies more swiftly, ultimately leading to improved medical outcomes. As of mid-2019, Tilos operates as a subsidiary of Merck & Co., Inc.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, focused on developing innovative therapies for bone-related diseases. Established in 2013, the company specializes in a prodrug platform that delivers therapeutics selectively to bone, addressing challenges associated with conventional drug delivery methods. Mesentech's lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic that aims to reverse bone loss associated with conditions such as osteoporosis and Duchenne muscular dystrophy. The company's proprietary technology enhances the delivery of small-molecule and biological drugs to the bone's surface and interior, allowing for more effective treatment while minimizing side effects. This approach is particularly significant given the inherent difficulty in accessing bone tissue due to its hard surface and low porosity. Mesentech's focus on selective drug delivery not only aims to improve treatment efficacy but also hopes to accelerate bone healing and address complications associated with low bone density disorders.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

Immune Design Corp., a clinical-stage immunotherapy company based in Seattle, Washington, focuses on enabling the body's immune system to combat diseases, with a primary emphasis on cancer treatment. The company leverages its ZVex and GLAAS discovery platforms to develop innovative therapies. Its lead product candidate is G100, currently in Phase II clinical trials for treating follicular non-Hodgkin lymphoma, both as a monotherapy and in combination therapy. Immune Design has collaboration and license agreements with Sanofi Pasteur. The company was founded in 2008 and operates under the umbrella of Merck & Co., Inc.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

Viralytics Limited is a biotechnology company based in Sydney, Australia, specializing in the development and commercialization of oncolytic immunotherapies for cancer treatment. The company’s lead product, CAVATAK, is a proprietary formulation of a common cold virus that is currently undergoing Phase Ib and Phase II clinical trials for various cancers, including melanoma, lung, and bladder cancer. In addition to CAVATAK, Viralytics is developing EVATAK, aimed at treating ovarian, prostate, and gastric cancers. The company leverages the cancer-targeting properties of benign viruses to enhance the efficacy of cancer therapies while minimizing side effects. Formerly known as Psiron Ltd., Viralytics rebranded in December 2006 and has operations in Newcastle, Australia. As of June 2018, Viralytics is a subsidiary of Merck & Co. Inc.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

IOmet Pharma Ltd. is a pharmaceutical company based in Edinburgh, United Kingdom, with an additional office in London. Founded in 2008, the company focuses on discovering and developing innovative medicines for cancer treatment, particularly in the areas of cancer immunotherapy and cancer metabolism. Its research includes the development of IDO, TDO, and dual-acting IDO/TDO inhibitors, along with GLUT1 inhibitors. IOmet Pharma operates in the preclinical stage of drug discovery, aiming to advance its therapeutic candidates for the benefit of patients with cancer. As of January 2016, the company functions as a subsidiary of Merck & Co., Inc.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

cCAM Biotherapeutics Ltd. is a clinical-stage biotechnology company based in Misgav, Israel, focused on the discovery and development of innovative immunotherapies for cancer treatment. The company is developing CM-10, an immunomodulatory antibody designed to enhance the immune system's ability to target and attack tumors by binding to CEACAM1, a protein that cancer cells exploit to evade immune responses. cCAM's lead therapeutic candidate, CM-24, is a humanized anti-CEACAM1 monoclonal antibody aimed at treating advanced and recurrent cancers, including melanoma, non-small-cell lung cancer, bladder, gastric, colorectal, and ovarian cancers. Established in 2010, cCAM Biotherapeutics aims to provide effective treatment options for patients facing various malignancies.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Founded in 1992, Cubist Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing pharmaceutical products that address unmet medical needs in acute care settings. Its primary product is CUBICIN, the first antibiotic in its class, used for treating serious infections. The company's pipeline includes drugs targeting Clostridium difficile-associated diarrhea, multi-drug resistant Gram-negative infections, and respiratory syncytial virus infections.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Idenix Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs for the treatment of viral diseases, primarily targeting hepatitis C virus (HCV). With operations in the United States and Europe, the company's research efforts have led to significant advancements in HCV treatment, including the completion of a proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. Idenix has also initiated a phase IIa clinical trial to evaluate its lead drug candidate, IDX184, in combination with existing therapies. In addition to HCV, Idenix is developing products and candidates aimed at treating hepatitis B virus (HBV), human immunodeficiency virus type I (HIV), and acquired immune deficiency syndrome (AIDS).

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development.

Vaximm is a biotechnology company dedicated to developing active immunotherapies, specifically vaccines, for cancer patients. Their primary focus is on targeting the tumor vasculature, which is crucial for tumor growth. The company's initial product candidate, VXM01, has demonstrated significant anti-tumor activity in various animal studies and was set to enter first human clinical trials in 2011. Vaximm's vaccines utilize oral T-cell activators based on modified attenuated bacteria, designed to target a broad range of cancer-related antigens, offering advanced treatment options for cancer patients.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

Frosst Iberica S.A. manufactures pharmaceutical products.

ImpactRx, Inc. is a promotion research organization serving the pharmaceutical industry in the United States. The company specializes in tracking and evaluating the effects of pharmaceutical promotions on physicians' prescribing behaviors. Utilizing its proprietary technology, ImpactRx collects and processes data regarding physicians' perceptions and activities, enabling pharmaceutical companies to assess and predict the effectiveness of their sales and marketing initiatives. The organization offers a variety of syndicated and semi-custom products focused on brand management, market research, sales management, managed care marketing, and oncology sales and marketing. These services support pharmaceutical and biotech companies in making informed decisions. Founded in 2000, ImpactRx is headquartered in Mount Laurel, New Jersey.

Schering-Plough Corporation is a prominent U.S.-based pharmaceutical manufacturer headquartered in Kenilworth, New Jersey. Founded in 1851 in Germany, the company operates across three primary segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. Schering-Plough focuses on the discovery, development, and marketing of a diverse range of pharmaceutical products, addressing conditions related to allergies, cancer, hepatitis, cardiovascular health, and the central and respiratory nervous systems. Notable products include the allergy medications Claritin and Clarinex, the anti-cholesterol drug Vytorin, and the brain tumor treatment Temodar. Additionally, the company encompasses well-known consumer brands such as Dr. Scholl's foot care and Coppertone skin care. Schering-Plough has been actively involved in the pharmaceutical industry and is recognized for its contributions to both human and animal health.

Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in oncology and genetic disorders. Founded in 2005, the company develops and commercializes a diverse array of diagnostic products and services aimed at improving patient management. Its offerings include various AmplideX reagents for detecting genetic markers, as well as comprehensive cancer diagnostic kits, such as QUANTIDEX and Signature assays that target specific mutations and gene fusions. Asuragen employs its patented Armored RNA technology in its diagnostics portfolio, which encompasses genetic and oncology testing products alongside industry-leading controls. The company also provides GLP testing services and operates a cGMP manufacturing facility, ensuring a seamless process from discovery to commercialization. With a focus on enhancing treatment outcomes through precise data, Asuragen plays a critical role in the medical community's efforts to improve patient care in oncology and genetics.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Abmaxis, Inc. is a biopharmaceutical company specializing in the discovery, optimization, and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. It operates in the biotechnology, pharmaceutical, and life science industries, providing drug discovery services to clients and collaborating with global biotech and pharmaceutical partners to build internal product pipelines.

GlycoFi is a biotech company focused on developing biotherapeutics utilizing glycan optimization technology. Founded in 2000 and based in Lebanon, New Hampshire, the firm specializes in a proprietary protein manufacturing process that employs engineered yeast strains to achieve precise human glycosylation. This innovative approach enables the creation of therapeutic proteins, which are essential for drug development. GlycoFi aims to build its own pipeline of products while also collaborating with other pharmaceutical companies to enhance their drug offerings. In 2006, GlycoFi became a subsidiary of Merck & Co. Inc., further expanding its capabilities in the biotherapeutics field.

Cytel specializes in providing statistical software and advanced analytics tailored for clinical trial design and execution. With over thirty years of experience, the company supports biotech and pharmaceutical firms in managing uncertainty and making evidence-based decisions. Cytel's offerings include industry-leading software, data-driven analytics, and strategic consulting, focusing on areas such as protocol development, regulatory support, and enrollment forecasting. By delivering real-world evidence and operational expertise, Cytel helps clients enhance efficiency and reduce costs in the life sciences development process.

ImpactRx, Inc. is a promotion research organization serving the pharmaceutical industry in the United States. The company specializes in tracking and evaluating the effects of pharmaceutical promotions on physicians' prescribing behaviors. Utilizing its proprietary technology, ImpactRx collects and processes data regarding physicians' perceptions and activities, enabling pharmaceutical companies to assess and predict the effectiveness of their sales and marketing initiatives. The organization offers a variety of syndicated and semi-custom products focused on brand management, market research, sales management, managed care marketing, and oncology sales and marketing. These services support pharmaceutical and biotech companies in making informed decisions. Founded in 2000, ImpactRx is headquartered in Mount Laurel, New Jersey.

Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

Medco Containment Services Inc., one of the largest mail-order pharmacy and managed-care drug companies.

Founded in 2010, Redica Systems operates a regulatory compliance platform that provides data-driven insights to professionals in regulated industries worldwide. Its services include FDA library access/search, regulatory profiles, and benchmarking/trending tools. Serving over 200 customers, including major pharmaceutical, medical device, and food companies, Redica empowers clients to quantify risk signals, identify market opportunities, and improve product quality.